Arrowstreet Capital, Limited Partnership Intra Cellular Therapies, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$64.76 - $79.84 $252,952 - $311,855	3,906 New	3,906 $268,000
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $528,713 - $642,541	9,671 New	9,671 $612,000
Q2 2022 Aug 15, 2022	SELL	$43.0 - $65.64 $200,509 - $306,079	-4,663 Reduced 33.54%	9,238 $527,000
Q1 2022 May 13, 2022	BUY	$38.74 - $62.09 $538,524 - $863,113	13,901 New	13,901 $851,000
Q4 2020 Feb 12, 2021	SELL	$23.34 - $32.22 $511,589 - $706,230	-21,919 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$17.61 - $31.86 $385,993 - $698,339	21,919 New	21,919 $562,000
Q1 2020 May 15, 2020	SELL	$12.31 - $33.12 $107,097 - $288,144	-8,700 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$7.26 - $38.49 $63,162 - $334,863	8,700 New	8,700 $298,000

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.92B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.